TABLE 3

Clinical and biochemical data of 4,251 middle-aged glucose tolerant white subjects from the Inter99 cohort when classified in accordance to their genotype of the Asp358Ala polymorphism of IL6R

Asp/AspAsp/AlaAla/AlaP*PrecessivePdominant
n (men/women)1,495 (682/813)2,013 (942/1,071)743 (348/395)
Age (years)45 ± 845 ± 845 ± 8
BMI (kg/m2)25.6 ± 4.125.5 ± 4.025.4 ± 4.0NSNSNS
Waist-to-hip ratio0.84 ± 0.090.84 ± 0.080.84 ± 0.08NSNSNS
Plasma glucose at 0 min (mmol/l)5.3 ± 0.45.3 ± 0.45.3 ± 0.4NSNSNS
Plasma glucose at 120 min (mmol/l)5.5 ± 1.15.5 ± 1.15.4 ± 1.1NSNSNS
Incremental AUC glucose (mmol/l)181 ± 104184 ± 99179 ± 98NSNSNS
Serum insulin at 0 min (pmol/l)38 ± 2437 ± 2337 ± 23NSNSNS
Serum insulin at 120 min (pmol/l)167 ± 121167 ± 133169 ± 139NSNSNS
Incremental AUC insulin (pmol/l)21,151 ± 13,35820,878 ± 13,28820,782 ± 12,811NSNSNS
Insulinogenic index insulin31 ± 2131 ± 1931 ± 18NSNSNS
HOMA-IR9.1 ± 5.78.8 ± 5.68.8 ± 5.7NSNSNS
Serum cholesterol (mmol/l)5.4 ± 1.05.4 ± 1.05.4 ± 1.0NSNSNS
Serum HDL cholesterol (mmol/l)1.45 ± 0.401.47 ± 0.401.47 ± 0.40NSNSNS
Serum triglycerides (mmol/l)1.16 ± 0.701.18 ± 0.801.21 ± 1.53NSNSNS
  • Data are means ± SD.

  • *

    * Comparing Asp/Asp, Asp/Ala, and Ala/Ala;

  • comparing Asp/Asp and Asp/Ala with Ala/Ala; and

  • comparing Asp/Asp with Asp/Ala and Ala/Ala, all after adjustment for age, BMI, and sex. AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance index; NS, not significant.